DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue relian

A TRANSFORMATIONAL PLACENTAL BIOLOGICS

COMPANY H.C. Wainwright Global Investment Conference May 2022 Exhibit 99.1

DISCLAIMER & CAUTIONARY STATEMENTS

This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from

those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: future sales or sales growth; the Company's expectations regarding its mdHACM product's potential use as a safe and

effective treatment option, and that it may be an effective treatment for persons battling inflammatory conditions; the Company's plans for meetings with the U.S. Food & Drug Administration (FDA), and planned biologics license application

(BLA) submissions to the FDA, and their timing; plans for future clinical trials, including the Company's decision to pursue or not pursue, and their timing; the effectiveness of amniotic tissue as a therapy for any particular indication or

condition; estimates of potential market size for the Company's current and future products; plans for expansion outside of the U.S.; expected spending on clinical trials and research and development; the Company's long-term strategy for

value creation, the status of its pipeline products, expectations for future products, and expectations for future growth;

DISCLAIMER & CAUTIONARY STATEMENTS

Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking

statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could

cause actual results to differ from expectations include: future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; the results of a clinical trial or trials may

not demonstrate that the product is safe or effective, or may have little or no statistical value; the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public

announcements; the timing of any meeting with the FDA depends on many factors and is outside of the Company's control, and the results from any meeting are uncertain; a BLA submission requires a number of prerequisites, including favorable

study results and statistical support, and completion of a satisfactory FDA inspection of the Company's manufacturing facility or facilities; plans for future clinical trials depend on the results of pending clinical trials, discussion with

the FDA, and other factors; and conducting clinical trials is a time-consuming, expensive, and uncertain process; the future market for the Company's products can depend on regulatory approval of such products, which might not occur at all or

when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company's products, market acceptance of the Company's products, and adequate reimbursement for

such therapies; the process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or

approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; whether there is full access to

hospitals and healthcare provider facilities, as a continuation or escalation of access restrictions or lockdown orders resulting from the ongoing COVID-19 pandemic; and expected spending can depend in part on the results of pending clinical trials.

The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date

of this presentation and the Company assumes no obligation to update any forward-looking statement.

LEADING PRODUCT PORTFOLIO POSITIONED

FOR GROWTH 83.1% TTM Gross Margin $257.5M TTM Net Sales $504M Market Cap4 (1) TTM refers to the trailing twelve months ended March 31, 2022, and is calculated for any measure by adding the results for the full year ended December 31, 2021 to the

results for the quarter ended March 31, 2022 and subtracting the results for the quarter ended March 31, 2021; Adjusted EBITDA is a non-GAAP measure consisting of GAAP net loss excluding: (i) depreciation, (ii) amortization of intangibles, (iii)

interest expense, (iv) income tax provision, (v) costs incurred in connection with Audit Committee Investigation and Restatement, (vi) impairment of intangible assets, and (vii) share-based compensation. Refer to Item 7 of our Annual Report on Form

10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022 (the "2021 Annual Report") for defined terms and reconciliation to the nearest GAAP measure. (2) Year-over-year growth based on sales of our Advanced Wound

Care products, which excludes Section 351 products (as defined in our 2021 Annual Report) for Q1 2022 compared to Q1 2021. (3) As of December 31, 2021. (4) Based on closing stock price on May 23, 2022. Assumes conversion of Series B shares. (5) As

of May 23, 2022; (6) UnitedHealthcare Commercial Medical Policy 2020T0592H; Aetna Policy: CPB# 331, Skin and Soft Tissue Substitutes; Anthem Policy: SURG.00011, Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft

Tissue Graf ting; Cigna Policy: 0068, Tissue-Engineered Skin Substitutes; Humana Policy: HCS-0370-037, Skin and Tissue Substitutes. (7) Safiri S, Kolahi A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a

systematic analysis of the Global Burden of Disease Study 2017Annals of the Rheumatic Diseases 2020;79:819-828. (8) Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates. Adv Wound Care (New Rochelle). 2019; 8(2):39-48.

doi:10.1089/wound.2019.0946; (9) BioMed GPS SmartTrak; (10) Tettelbach, WH, Armstrong, DG, Chang, TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. Journal of Wound Care

2022 31:Sup2, S10-S31. (11) Snyder DL, et al. Agency for Healthcare Research and Quality. https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id109TA.pdf. Published February 2020. Accessed October 13, 2021. AHRQ = Agency for

Healthcare Research and Quality 100% National Payor Coverage for DFUs6 800+ Employees3 $12.0M TTM Adjusted EBITDA1 MDXG $75.7M Cash at 3/31/22 2,000,000+ Allografts Distributed5 Year-over-year Revenue growth in Wound Care & Surgical business2

($12.4M) TTM Net Loss 13.4% 30M (U.S.) with diabetes8 2.9M chronic wounds9 In a recent peer-reviewed study, the average cost/episode with EPIFIX was 42% of the low risk-of-bias studies in AHRQ assessment were on MIMEDX products11 300M+ people

worldwide suffering from hip and knee OA7 ~$3000 less versus other advanced treatments10 50+ Clinical & Scientific Publications

COMPELLING INVESTMENT THESIS Foundation

Positioned for Growth 11-14% Mid-Term Growth Expectations Plan to Commence Pivotal KOA Clinical Trial Program in 2022 View to Free Cash Flow

THE TRANSFORMATIONAL POTENTIAL Existing

2022-2023 2026+ Advanced Wound Care Advanced Wound Care Surgical Recovery Japan + + Advanced Wound Care Surgical Recovery Japan + + + Other OUS + $1.1B $2.7B Knee Osteoarthritis $4B+ DMOAD Transforming medicine in large and high growth markets with

significant unmet needs BioMed GPS SmartTrak; GlobalData Tissue Engineered-Skin Sub Data Model Wound Management Year 2020 - retrieved Sept 2021; GlobalData Knee Reconstruction Data Model United States 2020; 3rd party proprietary assessment;

Management estimates; OUS = Outside of United States; DMOAD = Disease Modifying Osteoarthritis Drug

SIGNIFICANT UNMET CLINICAL NEED IN KNEE

OSTEOARTHRITIS Market Sizing Algorithm 19 Million Patients with KOA 12 Million Target for HA Injections Value Multipliers DMOAD substantially amplifies market opportunity Product Label Dosing Regimen Bilateral Application Prophylactic Use Place in

Treatment Algorithm Clinical Trial Results DMOAD Multiple factors drive overall transformation GlobalData: 2020 Orthopedic Devices Knee Reconstruction US (2015-2030); GlobalData: Viscosupplementation Model (HA) U.S. (2015-2030); KOA = Knee

Osteoarthritis; HA = Hyaluronic Acid

mdHACM HOLDS POTENTIAL TO REDUCE PAIN

AND INCREASE FUNCTION IN KOA Knee Osteoarthritis 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 2022 2023 2024 2025 2026 2027 Phase 2B study did not meet primary endpoints across 446 patient population, but demonstrated statistically significant and clinically

meaningful improvement within pre-interim analysis cohort (n=190) Plan to commence registrational KOA Clinical Trial Program in 2022 Anticipate BLA filing in late-2025 with greater probability of success Trial initiation Est. launch Est. BLA filing

190-patient Cohort 3 months 6 months WOMAC Pain p=0.032 p=0.009 WOMAC Function p=0.046 p=0.009 WOMAC Total p=0.038 p=0.008 MIMEDX has learned much from this trial and I think they will further refine the final product characterization and we should

be optimistic that we will see positive results from future trials with this product. Dr. Vibeke Strand MIMEDX Investor Day (Dec. 7, 2021) Pre-Interim Analysis Cohort mdHACM = micronized dehydrated Human Amnion Chorion Membrane; WOMAC = Western

Ontario and McMaster Universities Osteoarthritis Index; BLA = Biologics License Application; Timeline represents current plans and estimates only. Actual results and timing may differ materially. There can be no assurance that clinical trials are

conducted or completed on schedule, that trial results are favorable, or that we obtain regulatory approval for our products and indications.

mdHACM HOLDS POTENTIAL TO REDUCE PAIN

AND INCREASE FUNCTION IN KOA 190-patient Cohort mdHACM Placebo p-value Pain Score % Improvement Pain Score % Improvement WOMAC Pain at Baseline 10.0 n/a 9.6 n/a n/a WOMAC Pain at 3-months 4.9 51% 5.7 40% p=0.032 WOMAC Pain at 6-months 3.8 62% 5.2

45% p=0.009 Phase 2B study did not meet primary endpoints across 446 patient population, but demonstrated statistically significant and clinically meaningful1 improvement within pre-interim analysis cohort (n=190) Pre-Interim Analysis Cohort mdHACM

demonstrated a strong and clinically meaningful improvement from baseline over placebo in 190 patient pre-interim analysis cohort (1) Minimal-Clinically Important Improvement (MCII), defined as the smallest change in measurement that signifies an

important improvement in a patient's symptom,; Dowsey MM, Choong PF. The utility of outcome measures in total knee replacement surgery. Int J Rheumatol. 2013;2013:506518. doi: 10.1155/2013/506518. Epub 2013 Oct 31. PMID: 24288541; PMCID:

PMC3833283.; mdHACM = micronized dehydrated Human Amnion Chorion Membrane; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index

Inorganic opportunities and future

year new product launches would present additional upside opportunity Future year new product A Future year new product B Accretive Inorganic Opportunities + + = MID-TERM GROWTH EXPECTATIONS DRIVEN BY TREATMENT TRANSFORMATION AND ONGOING PORTFOLIO

INNOVATION Management estimates of annual revenue growth rate.

EXPANSION INTO SURGICAL RECOVERY

MARKET PROPELS GROWTH Total Addressable Market +10% Annual Tissue augmentation Barrier properties Surgical closure Growth Drivers: Aging population Increasing obesity Awareness & penetration $0.9B $1.3B BioMed GPS SmartTrak; 3rd party

proprietary assessment; Management estimates

MULTIPLE OPPORTUNITIES TO EXPAND

EXISTING PROCEDURE BASE SURGICAL SPECIALTY PROCEDURAL EXAMPLE Vascular Incision Management Amputation Orthopaedics Joint Replacement Rotator Cuff Repair Spine Lumbar Decompression General Surgery Bowel Anastomosis Gynecology C-Section Incisions

Hysterectomy Plastics Mohs Defect Reconstruction Incision Management

SURGICAL RECOVERY GROWTH DRIVEN BY

MARKET DEVELOPMENT Expand Reach in O.R. Procedural Training KOL Development by Specialty New Product Launches Clinical & Economic Evidence Targeting Unmet Needs Leveraging Portfolio Tissue Handling Antimicrobial Platform Functional

OPPORTUNITIES TO EXTEND LEADERSHIP

IN DIFFERENTIATED CLINICAL EVIDENCE 29% 2% Experienced Complications: Autologous Flap/ FTSG EPIFIX Mohs Defect Repair with Dehydrated Human Amnion/Chorion Membrane1 Outcomes comparing autologous flaps/grafts and dHACM Patients receiving flaps or

grafts were 19x more likely to experience poor cosmesis or revisions Poor Cosmesis: 15% 0% Autologous Flap/ FTSG EPIFIX 10% 0% Autologous Flap/ FTSG EPIFIX Patients receiving flaps or grafts were 12x more likely to have infections or surgical

reintervention Infections: Revisions: Surgical Reintervention: 8% 0% Autologous Flap/ FTSG EPIFIX 10% Autologous Flap/ FTSG EPIFIX 2% AREAS OF FOCUS Chronic wound clinical & health economic outcomes Treating challenging surgical wounds Complex

incision management Orthopaedic surgical recovery (1) Toman J, Michael GM, Wisco OJ, Adams JR, Hubbs BS. Mohs Defect Repair with Dehydrated Human Amnion/Chorion Membrane. Facial Plast Surg Aesthet Med. 2021 Oct 29. doi: 10.1089/fpsam.2021.0167. Epub

ahead of print. PMID: 34714143. FTSG = Full Thickness Skin Grafts

2022 LAUNCHES EXPAND PLACENTAL

PORTFOLIO AMNIOEFFECT Placental Collagen Matrix Particulate format fulfills key portfolio gap Retains key extracellular matrix components Wide range of sizes up to 9 cm x 20 cm Improved handling for minimally invasive procedures Anticipate

two new, organic products launched per year; future year new product launches would present additional upside opportunity

Why This is the Right Team: Positive

Financial Metrics Showing Growth, Steps Company has Taken to Address Underperformance--- ADVANCED WOUND CARE CONTINUES TO EXHIBIT STRONG DOUBLE-DIGIT GROWTH (1) Adjusted net sales excludes revenue recognized from cash collections on remaining

contracts. Adjusted net sales is a non-GAAP measurement. (2) Section 361 includes Tissue + Cord sales. Section 351 includes Micronized + Particulate sales. (3) TTM refers to the trailing twelve months ended March 31, 2022, and is calculated for any

measure by adding the results for the full year ended December 31, 2021 to the results for the quarter ended March 31, 2022 and subtracting the results for the quarter ended March 31, 2021. Adjusted Net Sales1 Net Sales Advanced Wound Care / Section

361 Net Sales2 +16.7% Results for TTM3 Ended March 31 ($M) +4.5% +5.7% Adjusted Net Sales1 Net Sales Advanced Wound Care / Section 361 Net Sales2 Results for the Three Months Ended March 31 ($M) (1.8%) +13.4% (1.3%) 2021 2022 2021 2022 2021 2022

2021 2022 2021 2022 2021 2022

Why This is the Right Team: Positive

Financial Metrics Showing Growth, Steps Company has Taken to Address Underperformance--- CONSISTENT OUTPERFORMANCE COMPARED TO CONSENSUS WITH STRONG, SUSTAINED GROWTH FROM THE COMPANY'S CORE BUSINESS Multiple Quarters With Strong Growth in the

Company's Advanced Wound Care / Section 361 Business Quarterly Revenue Performance Compared to Consensus Since NASDAQ Relisting Consensus Beat / Miss % Beat / Miss 10.6% 0.1% 16.0% 4.7% 5.8% 8.9% Year-over-Year Revenue Growth 29.5% 13.1% 12.9%

13.4% 6.2% 5.6% (1) 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 (1) The increase was primarily the result of an increase in sales volume over the prior year period, which was previously impacted by the COVID-19 pandemic. The impact

on the prior year's net sales resulted primarily from the COVID-19 pandemic causing cancellations and postponements for many elective procedures across the U.S.

EXISTING CASH LEVELS ARE SUFFICIENT

TO SUPPORT NEAR-TERM R&D EFFORTS Free cash flow neutral Free cash flow positive Increase Decrease Total Business Results represents expected Adjusted EBITDA. Other Uses include debt service, and investigation, restatement and related expenses.

Dec 21 Business Results Business Results Capital Expenditures Capital Expenditures Other Uses Other Uses Dec 22 Dec 23 Cash and cash equivalents at March 31, 2022 = $75.7 million Expect two clinical trials for Knee OA indication

to cost less than $30 million; incurred over three years Over the 12 - 15 months ending December 2022, we continue to expect: Base business to be cash flow neutral Overall revenue to return to levels consistent with those prior to end of

Enforcement Discretion(1)

PIONEER IN PLACENTAL BIOLOGICS

Distinct drivers of significant shareholder value with current and future growth potential Wound Care & Surgical Recovery Regenerative Medicine & Biologics Innovation

2022 OBJECTIVES SUPPORT CURRENT AND

FUTURE GROWTH POTENTIAL R&D Initiate Phase 3 KOA Clinical Studies Increase Product Vitality Index Advance body of scientific evidence Operations Implement CGMP throughout supply chain Leverage cost base through production efficiencies Optimize